Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Can a selective PPAR? modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

Can a selective PPAR? modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care. 2014 Jul; 37(7):1918-23.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.